504 related articles for article (PubMed ID: 28249162)
1. BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1.
Hogg SJ; Vervoort SJ; Deswal S; Ott CJ; Li J; Cluse LA; Beavis PA; Darcy PK; Martin BP; Spencer A; Traunbauer AK; Sadovnik I; Bauer K; Valent P; Bradner JE; Zuber J; Shortt J; Johnstone RW
Cell Rep; 2017 Feb; 18(9):2162-2174. PubMed ID: 28249162
[TBL] [Abstract][Full Text] [Related]
2. Co-inhibition of BET proteins and NF-κB as a potential therapy for colorectal cancer through synergistic inhibiting MYC and FOXM1 expressions.
Wu T; Wang G; Chen W; Zhu Z; Liu Y; Huang Z; Huang Y; Du P; Yang Y; Liu CY; Cui L
Cell Death Dis; 2018 Feb; 9(3):315. PubMed ID: 29472532
[TBL] [Abstract][Full Text] [Related]
3. BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer.
Jing X; Shao S; Zhang Y; Luo A; Zhao L; Zhang L; Gu S; Zhao X
Exp Cell Res; 2020 Jul; 392(2):112034. PubMed ID: 32339606
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.
Abruzzese MP; Bilotta MT; Fionda C; Zingoni A; Soriani A; Vulpis E; Borrelli C; Zitti B; Petrucci MT; Ricciardi MR; Molfetta R; Paolini R; Santoni A; Cippitelli M
J Hematol Oncol; 2016 Dec; 9(1):134. PubMed ID: 27903272
[TBL] [Abstract][Full Text] [Related]
5. MYC inhibition increases PD-L1 expression induced by IFN-γ in hepatocellular carcinoma cells.
Zou J; Zhuang M; Yu X; Li N; Mao R; Wang Z; Wang J; Wang X; Zhou H; Zhang L; Shi Y
Mol Immunol; 2018 Sep; 101():203-209. PubMed ID: 30007230
[TBL] [Abstract][Full Text] [Related]
6. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.
Goodman A; Patel SP; Kurzrock R
Nat Rev Clin Oncol; 2017 Apr; 14(4):203-220. PubMed ID: 27805626
[TBL] [Abstract][Full Text] [Related]
7. Co-inhibition of BET proteins and PD-L1 as a potential therapy for OSCC through synergistic inhibition of FOXM1 and PD-L1 expressions.
Wang W; Tan J
J Oral Pathol Med; 2019 Oct; 48(9):817-825. PubMed ID: 31177574
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in Neuroblastoma.
Melaiu O; Mina M; Chierici M; Boldrini R; Jurman G; Romania P; D'Alicandro V; Benedetti MC; Castellano A; Liu T; Furlanello C; Locatelli F; Fruci D
Clin Cancer Res; 2017 Aug; 23(15):4462-4472. PubMed ID: 28270499
[No Abstract] [Full Text] [Related]
9. BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer.
Wang J; Jia Y; Zhao S; Zhang X; Wang X; Han X; Wang Y; Ma M; Shi J; Liu L
Oncogene; 2017 Nov; 36(45):6235-6243. PubMed ID: 28714960
[TBL] [Abstract][Full Text] [Related]
10. PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas.
Wang Y; Wu L; Tian C; Zhang Y
Ann Hematol; 2018 Feb; 97(2):229-237. PubMed ID: 29128997
[TBL] [Abstract][Full Text] [Related]
11. HDAC3 Inhibition Upregulates PD-L1 Expression in B-Cell Lymphomas and Augments the Efficacy of Anti-PD-L1 Therapy.
Deng S; Hu Q; Zhang H; Yang F; Peng C; Huang C
Mol Cancer Ther; 2019 May; 18(5):900-908. PubMed ID: 30824609
[TBL] [Abstract][Full Text] [Related]
12. Interplay between interferon regulatory factor 1 and BRD4 in the regulation of PD-L1 in pancreatic stellate cells.
Ebine K; Kumar K; Pham TN; Shields MA; Collier KA; Shang M; DeCant BT; Urrutia R; Hwang RF; Grimaldo S; Principe DR; Grippo PJ; Bentrem DJ; Munshi HG
Sci Rep; 2018 Sep; 8(1):13225. PubMed ID: 30185888
[TBL] [Abstract][Full Text] [Related]
13. BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression.
Zhu H; Bengsch F; Svoronos N; Rutkowski MR; Bitler BG; Allegrezza MJ; Yokoyama Y; Kossenkov AV; Bradner JE; Conejo-Garcia JR; Zhang R
Cell Rep; 2016 Sep; 16(11):2829-2837. PubMed ID: 27626654
[TBL] [Abstract][Full Text] [Related]
14. Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells.
Homma S; Hayashi K; Yoshida K; Sagawa Y; Kamata Y; Ito M
Int Immunopharmacol; 2018 Jan; 54():39-45. PubMed ID: 29100036
[TBL] [Abstract][Full Text] [Related]
15. JQ1-Loaded Polydopamine Nanoplatform Inhibits c-MYC/Programmed Cell Death Ligand 1 to Enhance Photothermal Therapy for Triple-Negative Breast Cancer.
Tian Y; Wang X; Zhao S; Liao X; Younis MR; Wang S; Zhang C; Lu G
ACS Appl Mater Interfaces; 2019 Dec; 11(50):46626-46636. PubMed ID: 31751121
[TBL] [Abstract][Full Text] [Related]
16. BET inhibitors repress expression of interferon-stimulated genes and synergize with HDAC inhibitors in glioblastoma.
Gusyatiner O; Bady P; Pham MDT; Lei Y; Park J; Daniel RT; Delorenzi M; Hegi ME
Neuro Oncol; 2021 Oct; 23(10):1680-1692. PubMed ID: 33987681
[TBL] [Abstract][Full Text] [Related]
17. MYC regulates the antitumor immune response through CD47 and PD-L1.
Casey SC; Tong L; Li Y; Do R; Walz S; Fitzgerald KN; Gouw AM; Baylot V; Gütgemann I; Eilers M; Felsher DW
Science; 2016 Apr; 352(6282):227-31. PubMed ID: 26966191
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition.
Mao W; Ghasemzadeh A; Freeman ZT; Obradovic A; Chaimowitz MG; Nirschl TR; McKiernan E; Yegnasubramanian S; Drake CG
J Immunother Cancer; 2019 Oct; 7(1):277. PubMed ID: 31653272
[TBL] [Abstract][Full Text] [Related]
19. The proto-oncogene Bcl3 induces immune checkpoint PD-L1 expression, mediating proliferation of ovarian cancer cells.
Zou Y; Uddin MM; Padmanabhan S; Zhu Y; Bu P; Vancura A; Vancurova I
J Biol Chem; 2018 Oct; 293(40):15483-15496. PubMed ID: 30135206
[TBL] [Abstract][Full Text] [Related]
20. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.
Seifert AM; Zeng S; Zhang JQ; Kim TS; Cohen NA; Beckman MJ; Medina BD; Maltbaek JH; Loo JK; Crawley MH; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
Clin Cancer Res; 2017 Jan; 23(2):454-465. PubMed ID: 27470968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
